Electroacupuncture for shingles nerve pain: what a new sham-controlled trial actually shows

Anyone who has had a serious shingles episode knows the worst version is not the rash. It is the nerve pain that can linger for months or years after the skin has healed. Postherpetic neuralgia (PHN), the persistent burning, stabbing, or aching pain that follows a herpes zoster outbreak, is one of the most stubborn neuropathic pain syndromes in medicine. Conventional options exist (gabapentin, pregabalin, tricyclic antidepressants, lidocaine patches, capsaicin), but the relief is partial and the side effects are common. A new multicenter trial in JAMA Neurology tested whether electroacupuncture, compared with a sham version, could reduce PHN pain in a meaningfully rigorous way. The result is a more useful addition than usual to a literature that has often suffered from small, low-quality studies.

Photo: Katherine Hanlon / Unsplash

What the research found

This was a multicenter, randomized, sham-controlled clinical trial conducted at seven tertiary hospitals in China between October 2020 and July 2022, with the last follow-up in September 2022 [1]. Out of 1,072 patients screened, 448 were randomized. They were adults aged 45 to 75 with PHN and moderate-to-severe pain (Numeric Rating Scale score of at least 4 out of 10). Two hundred twenty-five were assigned to true electroacupuncture and 223 to sham electroacupuncture. Both groups received 20 sessions over 4 weeks, followed by a 4-week observation period. The primary outcome was the change in pain score from baseline to week 4, and a participant was counted as a responder if they had at least a 30 percent reduction in their pain score. Three hundred eighty-three (85.49%) completed the trial.

At week 4, the electroacupuncture group had a greater decrease in the NRS score than the sham group (-1.52 vs -0.99). The adjusted mean difference between groups was -0.53 (95% CI, -0.61 to -0.43; P < .001). The responder rate in the electroacupuncture group was 46.68 percent, compared with 24.28 percent in the sham group, an adjusted risk difference of 22.40 percentage points (95% CI, 13.02% to 31.79%; P < .001). The benefits held through the 1-month follow-up. No clinically significant adverse events were observed.

Two points worth holding side by side. The average between-group difference in pain score (about half a point on a 10-point scale) is small in absolute terms. The minimum clinically important difference for chronic pain on the NRS is often cited as 1 to 2 points. The responder analysis, which doubles the proportion of people who achieved meaningful pain reduction, tells a more clinically interesting story. PHN is the kind of condition where pulling a meaningful subset of people from "not responding" to "responding" is clinically significant even when the average effect looks modest.

The bigger picture

This trial slots into a literature that has long suggested an effect but has often had design problems. A 2025 systematic review and meta-analysis in Medicine (Baltimore), the first to apply trial sequential analysis to the electroacupuncture and herpes zoster literature, pooled 19 randomized trials [2]. It reported standardized mean differences favoring electroacupuncture for VAS pain score (SMD -2.55), pain relief time, time to lesion scab, and (notably) a substantial reduction in the odds of developing PHN among patients treated for acute zoster (pooled OR 0.11). The same review found the combination of electroacupuncture plus standard antiviral and analgesic care outperformed electroacupuncture alone.

So the broader picture is: acupuncture, and specifically electroacupuncture, has shown signal across the herpes zoster spectrum, from the acute outbreak through the post-herpetic pain syndrome. Most of that work has come out of China and used active comparators or open designs that limit how strongly we can interpret a single trial. The new JAMA Neurology paper is one of the more rigorous additions because it used a sham control, was conducted across multiple sites, randomized over four hundred patients, and reported a clear responder analysis.

Two upstream points are worth naming. PHN is a complication you would much rather avoid than treat. The recombinant zoster vaccine (Shingrix) is highly effective at preventing herpes zoster and, when zoster does occur, reduces the risk of progressing to PHN. The American Centers for Disease Control and Prevention recommends it for adults 50 and older, and for younger adults who are immunocompromised. For anyone in those groups who has not had the vaccine, that conversation belongs upstream of any pain-management discussion.

The naturopathic lens

PHN is a neuropathic pain condition that combines peripheral nerve damage from the viral outbreak with central sensitization in the spinal cord and brain. The pain system has been hurt and then rewired to amplify what comes through. That is why conventional analgesics often disappoint and why interventions that work on neural modulation (rather than purely on biochemistry) can have a different kind of effect.

Acupuncture works through several plausible mechanisms here. It activates descending pain-inhibitory pathways. It modulates inflammatory cytokines locally and systemically. It influences central sensitization through repeated, dose-dependent stimulation of nerve fibers. Electroacupuncture adds a defined frequency and intensity of stimulation that may strengthen those effects. None of this is mysterious anymore; the neuroscience has caught up with what acupuncturists have observed clinically for decades.

In clinic, when a patient comes in dealing with active zoster or with PHN that has settled in, the work is broader than picking one therapy. Acute zoster benefits from prompt antiviral treatment when caught early, plus nervous-system support (sleep, stress load, nutrient status including B12 and zinc, anti-inflammatory diet, gentle nerve-supportive botanicals like St. John's Wort topically or lemon balm) and pain-management options that fit the patient's situation. PHN that has already developed is a longer game: nervous-system retraining, sleep work, addressing any concurrent depression and anxiety (which dial pain up), and integration of body-based modalities like acupuncture, gentle movement, and graded sensory rehabilitation. The new trial supports adding electroacupuncture to that integrative picture with more confidence than before.

How to apply this in your own life

A few practical reads if you or someone you care about is dealing with active shingles or PHN:

1. Prevention is the most upstream step. If you are 50 or older, or younger and immunocompromised, and you have not had the recombinant zoster vaccine, that is a conversation to have with your clinician. Vaccination reduces both the risk of herpes zoster and the risk of PHN if zoster does occur.

2. If you develop a shingles rash, treat it as urgent. Antiviral medications work best when started within 72 hours of rash onset and can reduce both the severity of the outbreak and the likelihood of PHN.

3. For active zoster, integrative care can include nervous-system support, sleep work, nutrient assessment, and anti-inflammatory dietary patterns alongside conventional antiviral and analgesic therapy.

4. For PHN that has already settled in, the new electroacupuncture trial supports trying a structured course of treatment with a licensed acupuncturist trained in pain conditions, ideally as part of a broader plan that also addresses sleep, mood, and central sensitization.

5. PHN is genuinely hard to treat. Expect a multi-modal plan, not a single fix, and partner with clinicians who treat the whole picture.

References

1. Chen L, Liu Q, Pei L, et al. Effect of Electroacupuncture on Postherpetic Neuralgia: A Randomized Clinical Trial. JAMA Neurol. Published online May 26, 2026. PMID: 42189557. DOI: 10.1001/jamaneurol.2026.1443. Full text.

2. Zhou Q, Jing M, Ren H, Li G, Wang Z. Efficacy of electroacupuncture on clinical signs and immunological factors in herpes zoster: The first systematic review, meta-analysis, and trial sequential analysis of randomized clinical trials. Medicine (Baltimore). 2025;104(12):e41458. PMID: 40128056. DOI: 10.1097/MD.0000000000041458.

This information is educational and is not medical advice. Shingles and postherpetic neuralgia should be evaluated and managed in partnership with qualified healthcare providers. Decisions about vaccination, antiviral therapy, prescription pain medications, and complementary approaches should be made with a clinician who knows your full medical history.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.